Friedrich Martin Wurst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Friedrich Martin Wurst has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Gregory E. Skipper
4 shared publicationsChrister Alling
3 shared publicationsJ Metzger
3 shared publicationsP Marques
3 shared publicationsWolfgang Weinmann
3 shared publications- Wolfgang Weinmann
Institute of Legal Medicine, Klinikum der Albert-Ludwigs-Universität Freiburg, Germany
3 shared publications
Latest Publications
- 15 July 2013
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 81 (09) , 493-502
Direkte Ethanolmetaboliten als Biomarker für Alkoholkonsum: Grundlagen und Anwendungen
Biomarker sind in Diagnose und Therapie alkoholbezogener Störungen in Ergänzung zu Selbstangaben von relevanter Bedeutung. Traditionelle Biomarker wie Gamma-Glutamyltranspeptidase (GGT) und mittleres korpuskuläres Volumen (MCV) sind indirekte Marker und werden durch Alter, Geschlecht und nicht alkoholbezogene Erkrankungen beeinflusst. Direkte Ethanolmetabolite wie Ethylglukuronid (EtG), Ethylsulfat (EtS) und Phosphatidylethanol (PEth) sind direkte Stoffwechselprodukte von Alkohol. Sie zeichnen sich durch hohe Sensitivität und Spezifität aus, decken ein komplementäres Zeitfenster des Konsumnachweises ab und werden seit einigen Jahren zunehmend routinemäßig eingesetzt. Direkte Ethanolmetabolite sind im Serum für Stunden, im Urin für bis zu 7 Tage, im Vollblut über 2 Wochen und in Haaren über Monate nachweisbar. Zu den Anwendungsbereichen gehören klinisch routinemäßige Anwendungen, der Einsatz in notfallmedizinischen Kontexten, Abstinenznachweis in Alkoholbehandlungsprogrammen, bei Fahreignungsuntersuchungen, Lebertransplantationen, betrieblicher Gesundheitsprävention sowie die Verwendung zur Abschätzung des Alkoholkonsums während der Schwangerschaft im Zusammenhang mit dem fetalen Alkohol-Syndrom. Durch ihre Eigenschaften eröffnen sie neue Perspektiven in Prävention, interdisziplinärer Kooperation, Diagnose und Therapie alkoholbezogener Störungen. In addition to self reports and questionnaires, biomarkers are of relevance in the diagnosis of and therapy for alcohol use disorders. Traditional biomarkers such as gamma-glutamyl transpeptidase or mean corpuscular volume are indirect biomarkers and are subject to the influence of age, gender and non-alcohol related diseases, among others. Direct metabolites of ethanol such as ethyl glucuronide (EtG), ethyl sulphate (EtS) and phosphatidylethanol (PEth) are direct metabolites of ethanol, that are positive after intake of ethyl alcohol. They represent useful diagnostic tools for identifying alcohol use even more accurately than traditional biomarkers. Each of these drinking indicators remains positive in serum and urine for a characteristic time spectrum after the cessation of ethanol intake – EtG and EtS in urine up to 7 days, EtG in hair for months after ethanol has left the body. Applications include clinical routine use, emergency room settings, proof of abstinence in alcohol rehabilitation programmes, driving under influence offenders, workplace testing, assessment of alcohol intake in the context of liver transplantation and foetal alcohol syndrome. Due to their properties, they open up new perspectives for prevention, interdisciplinary cooperation, diagnosis of and therapy for alcohol-related problems.
- 15 July 2013
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 81 (09) , 493-502
Direkte Ethanolmetaboliten als Biomarker für Alkoholkonsum: Grundlagen und Anwendungen
Biomarker sind in Diagnose und Therapie alkoholbezogener Störungen in Ergänzung zu Selbstangaben von relevanter Bedeutung. Traditionelle Biomarker wie Gamma-Glutamyltranspeptidase (GGT) und mittleres korpuskuläres Volumen (MCV) sind indirekte Marker und werden durch Alter, Geschlecht und nicht alkoholbezogene Erkrankungen beeinflusst. Direkte Ethanolmetabolite wie Ethylglukuronid (EtG), Ethylsulfat (EtS) und Phosphatidylethanol (PEth) sind direkte Stoffwechselprodukte von Alkohol. Sie zeichnen sich durch hohe Sensitivität und Spezifität aus, decken ein komplementäres Zeitfenster des Konsumnachweises ab und werden seit einigen Jahren zunehmend routinemäßig eingesetzt. Direkte Ethanolmetabolite sind im Serum für Stunden, im Urin für bis zu 7 Tage, im Vollblut über 2 Wochen und in Haaren über Monate nachweisbar. Zu den Anwendungsbereichen gehören klinisch routinemäßige Anwendungen, der Einsatz in notfallmedizinischen Kontexten, Abstinenznachweis in Alkoholbehandlungsprogrammen, bei Fahreignungsuntersuchungen, Lebertransplantationen, betrieblicher Gesundheitsprävention sowie die Verwendung zur Abschätzung des Alkoholkonsums während der Schwangerschaft im Zusammenhang mit dem fetalen Alkohol-Syndrom. Durch ihre Eigenschaften eröffnen sie neue Perspektiven in Prävention, interdisziplinärer Kooperation, Diagnose und Therapie alkoholbezogener Störungen. In addition to self reports and questionnaires, biomarkers are of relevance in the diagnosis of and therapy for alcohol use disorders. Traditional biomarkers such as gamma-glutamyl transpeptidase or mean corpuscular volume are indirect biomarkers and are subject to the influence of age, gender and non-alcohol related diseases, among others. Direct metabolites of ethanol such as ethyl glucuronide (EtG), ethyl sulphate (EtS) and phosphatidylethanol (PEth) are direct metabolites of ethanol, that are positive after intake of ethyl alcohol. They represent useful diagnostic tools for identifying alcohol use even more accurately than traditional biomarkers. Each of these drinking indicators remains positive in serum and urine for a characteristic time spectrum after the cessation of ethanol intake – EtG and EtS in urine up to 7 days, EtG in hair for months after ethanol has left the body. Applications include clinical routine use, emergency room settings, proof of abstinence in alcohol rehabilitation programmes, driving under influence offenders, workplace testing, assessment of alcohol intake in the context of liver transplantation and foetal alcohol syndrome. Due to their properties, they open up new perspectives for prevention, interdisciplinary cooperation, diagnosis of and therapy for alcohol-related problems.
- 1 March 2005
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 29 (3) , 465-473
Emerging Biomarkers: New Directions and Clinical Applications
This article summarizes content proceedings of a symposium held at the 2004 Research Society on Alcoholism Scientific Annual Meeting in Vancouver, Canada. The chairs were Friedrich M. Wurst and Raye Litten. The presentations were (1) Introduction, by Raye Litten; (2) Direct Ethanol Metabolites—On the Threshold From Science to Routine Use, by Friedrich M. Wurst; (3) Sialic Acid Index of Plasma Apolipoprotein J (SIJ) as a Viable Marker for Chronic Alcohol Consumption, by Philippe Marmillot; (4) The Emergence of Ethyl Glucuronide (EtG) Testing as a Tool in Monitoring Healthcare Professionals, by Gregory E. Skipper; (5) Application of Biomarkers for Alcohol Use Disorders in Clinical Practice, by Tim Neumann; (6) Utility of Biomarkers in Assessing the Efficacy of Medications for Treating Alcoholism, by Marty Javors; and (7) Discussion, by Raye Litten.
- 1 March 2005
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 29 (3) , 465-473
Emerging Biomarkers: New Directions and Clinical Applications
This article summarizes content proceedings of a symposium held at the 2004 Research Society on Alcoholism Scientific Annual Meeting in Vancouver, Canada. The chairs were Friedrich M. Wurst and Raye Litten. The presentations were (1) Introduction, by Raye Litten; (2) Direct Ethanol Metabolites—On the Threshold From Science to Routine Use, by Friedrich M. Wurst; (3) Sialic Acid Index of Plasma Apolipoprotein J (SIJ) as a Viable Marker for Chronic Alcohol Consumption, by Philippe Marmillot; (4) The Emergence of Ethyl Glucuronide (EtG) Testing as a Tool in Monitoring Healthcare Professionals, by Gregory E. Skipper; (5) Application of Biomarkers for Alcohol Use Disorders in Clinical Practice, by Tim Neumann; (6) Utility of Biomarkers in Assessing the Efficacy of Medications for Treating Alcoholism, by Marty Javors; and (7) Discussion, by Raye Litten.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (8) , 1220-1228
On Sensitivity, Specificity, and the Influence of Various Parameters on Ethyl Glucuronide Levels in Urine—Results From the WHO/ISBRA Study
Background: Ethyl glucuronide (EtG), a direct ethanol metabolite, seems to meet the need for a sensitive and specific marker for monitoring recent alcohol consumption in different settings. Our aim was to study sensitivity, specificity, and the influence of various parameters on EtG levels in urine.Patients and Methods: Urine samples for a total of 453 patients (373 male, 80 female) were statistically analyzed. The mean age was 37.1 years (median 36, SD 12.59), body mass index was 24.7, total ethanol consumed last month was 1817.66 g (each median), and 80 patients reported cannabis use within the last 30 days. Determination of EtG was performed with a liquid chromatography‐tandem mass spectrometry method with deuterium‐labeled EtG as internal standard.Results: For EtG in urine, a good correlation was found with other state markers and days of sobriety. In a regression analysis, age, gender, marijuana use, kidney disease, and total grams of ethanol consumed last month were the variables that significantly influenced EtG levels in contrast to race, smoking, body mass index, cirrhosis of liver, age began drinking regularly, packs of cigarettes smoked last month, and total body water. Furthermore, in a receiver operating characteristic curve analysis to distinguish between nondrinkers and individuals sober >4 days versus individuals drinking in the recent 4 days, area under the curve was 0.834. At a cutoff of 0.145 mg/liter, sensitivity was 83.5% and specificity 68.3%. A receiver operating characteristic curve was calculated for lifetime alcohol abuse or dependence against those who had never been abusers or dependent. In this case, subjects were either never dependent or lifetime dependent, but those currently dependent were excluded. The resulting area under the curve was 0.694. At a cutoff of 0.145 mg/liter, sensitivity was 73.8% and specificity 60.3%. For those with a self‐reported sobriety of less than 24 hr, the area under the curve was 0.899, sensitivity was 90.8%, and specificity was 76.5% at a cutoff of 0.435 mg/liter when we calculated nondrinkers and light drinkers against heavy drinkers and drinkers needing treatment. Cannabis‐using patients showed significant differences with regard to almost all state markers when compared with nonconsuming subjects.Conclusions: Age, gender, marijuana use, kidney disease, and total grams of ethanol consumed last month should be taken into consideration when interpreting results of EtG in urine. Sensitivity and specificity seem promising. Cannabis use can be regarded as an indicator for other serious mental problems in alcohol‐using subjects.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (8) , 1220-1228
On Sensitivity, Specificity, and the Influence of Various Parameters on Ethyl Glucuronide Levels in Urine—Results From the WHO/ISBRA Study
Background: Ethyl glucuronide (EtG), a direct ethanol metabolite, seems to meet the need for a sensitive and specific marker for monitoring recent alcohol consumption in different settings. Our aim was to study sensitivity, specificity, and the influence of various parameters on EtG levels in urine.Patients and Methods: Urine samples for a total of 453 patients (373 male, 80 female) were statistically analyzed. The mean age was 37.1 years (median 36, SD 12.59), body mass index was 24.7, total ethanol consumed last month was 1817.66 g (each median), and 80 patients reported cannabis use within the last 30 days. Determination of EtG was performed with a liquid chromatography‐tandem mass spectrometry method with deuterium‐labeled EtG as internal standard.Results: For EtG in urine, a good correlation was found with other state markers and days of sobriety. In a regression analysis, age, gender, marijuana use, kidney disease, and total grams of ethanol consumed last month were the variables that significantly influenced EtG levels in contrast to race, smoking, body mass index, cirrhosis of liver, age began drinking regularly, packs of cigarettes smoked last month, and total body water. Furthermore, in a receiver operating characteristic curve analysis to distinguish between nondrinkers and individuals sober >4 days versus individuals drinking in the recent 4 days, area under the curve was 0.834. At a cutoff of 0.145 mg/liter, sensitivity was 83.5% and specificity 68.3%. A receiver operating characteristic curve was calculated for lifetime alcohol abuse or dependence against those who had never been abusers or dependent. In this case, subjects were either never dependent or lifetime dependent, but those currently dependent were excluded. The resulting area under the curve was 0.694. At a cutoff of 0.145 mg/liter, sensitivity was 73.8% and specificity 60.3%. For those with a self‐reported sobriety of less than 24 hr, the area under the curve was 0.899, sensitivity was 90.8%, and specificity was 76.5% at a cutoff of 0.435 mg/liter when we calculated nondrinkers and light drinkers against heavy drinkers and drinkers needing treatment. Cannabis‐using patients showed significant differences with regard to almost all state markers when compared with nonconsuming subjects.Conclusions: Age, gender, marijuana use, kidney disease, and total grams of ethanol consumed last month should be taken into consideration when interpreting results of EtG in urine. Sensitivity and specificity seem promising. Cannabis use can be regarded as an indicator for other serious mental problems in alcohol‐using subjects.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 35A
PHOSPHATIDYLETHANOL (PETH): PRELIMINARY DATA ON SENSITIVITY, SPECIFICITY AND A CUTOFF.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 35A
PHOSPHATIDYLETHANOL (PETH): PRELIMINARY DATA ON SENSITIVITY, SPECIFICITY AND A CUTOFF.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 34A
INFLUENCE OF VARIOUS PARAMETERS ON ETHYL GLUCURONIDE LEVELS IN URINE ??? NEW RESULTS FROM THE WHO/ISBRA STUDY.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 34A
INFLUENCE OF VARIOUS PARAMETERS ON ETHYL GLUCURONIDE LEVELS IN URINE ??? NEW RESULTS FROM THE WHO/ISBRA STUDY.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 34A
GTOL-ELISA: A PROMISING TEST KIT FOR DETERMINATION OF RECENT ETHANOL INTAKE.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 34A
GTOL-ELISA: A PROMISING TEST KIT FOR DETERMINATION OF RECENT ETHANOL INTAKE.
- Open Access
- 2 July 2004
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 39 (5) , 445-449
ETHYL GLUCURONIDE: A BIOMARKER TO IDENTIFY ALCOHOL USE BY HEALTH PROFESSIONALS RECOVERING FROM SUBSTANCE USE DISORDERS
Aims: Physicians recovering from substance-related disorders are usually allowed to return to practice if they agree to remain abstinent from drugs, including alcohol, and to undergo random urine testing. Over 9000 physicians are currently involved in such monitoring programs in the US. To date, it has been difficult to adequately monitor abstinence from alcohol due to the short half-life of alcohol and no other highly specific marker. Ethyl glucuronide (EtG), a direct metabolite of alcohol, offers an extended window for assessment of drinking status (up to 5 days). Our aim was to assess the potential value of EtG testing in abstinence-based monitoring programs. Patients and methods: Urine samples were obtained from 100 participants in a physician monitoring program and additional samples were subsequently obtained ‘for cause’, ‘to verify positive urine alcohol, when drinking was denied’ and ‘in high risk individuals’. All participants had signed contracts agreeing to remain abstinent from mood-altering drugs, including alcohol, and had agreed to random urine testing. EtG was determined using LC/MS-MS in addition to standard testing. The main outcome measure were urine specimens positive for EtG versus those positive based on standard testing for alcohol and other drugs. Results: Among the initial 100 random samples collected, no sample was positive for alcohol using standard testing; however, seven were positive for EtG (0.5–196 mg/l), suggesting recent alcohol use. Subsequent EtG testing was performed clinically during the course of monitoring. Of the 18 tests performed to date, eight of eight tests performed ‘for cause’ were positive for EtG but negative for all other drugs including urine alcohol. All eight were confirmed positive by self reported drinking by the patient when confronted regarding the positive test result. Of six tests performed to ‘confirm a positive urine alcohol’ two were positive for EtG and confirmed positive by self reported drinking. For the other four samples, especially as two are from a diabetic, in vitro fermentation of ethanol is discussed. Conclusions: These data suggest that physicians in monitoring programs have a higher rate of unrecognized alcohol use than previously reported. Incorporation of EtG testing into alcohol abstinence monitoring can strengthen these programs.
- 2 July 2004
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 39 (5) , 445-449
Open AccessETHYL GLUCURONIDE: A BIOMARKER TO IDENTIFY ALCOHOL USE BY HEALTH PROFESSIONALS RECOVERING FROM SUBSTANCE USE DISORDERS
Aims: Physicians recovering from substance-related disorders are usually allowed to return to practice if they agree to remain abstinent from drugs, including alcohol, and to undergo random urine testing. Over 9000 physicians are currently involved in such monitoring programs in the US. To date, it has been difficult to adequately monitor abstinence from alcohol due to the short half-life of alcohol and no other highly specific marker. Ethyl glucuronide (EtG), a direct metabolite of alcohol, offers an extended window for assessment of drinking status (up to 5 days). Our aim was to assess the potential value of EtG testing in abstinence-based monitoring programs. Patients and methods: Urine samples were obtained from 100 participants in a physician monitoring program and additional samples were subsequently obtained ‘for cause’, ‘to verify positive urine alcohol, when drinking was denied’ and ‘in high risk individuals’. All participants had signed contracts agreeing to remain abstinent from mood-altering drugs, including alcohol, and had agreed to random urine testing. EtG was determined using LC/MS-MS in addition to standard testing. The main outcome measure were urine specimens positive for EtG versus those positive based on standard testing for alcohol and other drugs. Results: Among the initial 100 random samples collected, no sample was positive for alcohol using standard testing; however, seven were positive for EtG (0.5–196 mg/l), suggesting recent alcohol use. Subsequent EtG testing was performed clinically during the course of monitoring. Of the 18 tests performed to date, eight of eight tests performed ‘for cause’ were positive for EtG but negative for all other drugs including urine alcohol. All eight were confirmed positive by self reported drinking by the patient when confronted regarding the positive test result. Of six tests performed to ‘confirm a positive urine alcohol’ two were positive for EtG and confirmed positive by self reported drinking. For the other four samples, especially as two are from a diabetic, in vitro fermentation of ethanol is discussed. Conclusions: These data suggest that physicians in monitoring programs have a higher rate of unrecognized alcohol use than previously reported. Incorporation of EtG testing into alcohol abstinence monitoring can strengthen these programs.
- Open Access
- 1 January 2004
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 39 (1) , 33-38
CONCENTRATION OF FATTY ACID ETHYL ESTERS IN HAIR OF ALCOHOLICS: COMPARISON TO OTHER BIOLOGICAL STATE MARKERS AND SELF REPORTED-ETHANOL INTAKE
Aims: In a variety of clinical and forensic situations long term use of alcohol must be monitored. In this project we explore the utility of fatty acid ethyl esters (FAEE) in this regard. Additionally, we propose a cut-off value of FAEE to distinguish teetotallers/moderate/social drinkers from alcoholics or individuals drinking at harmful levels. Patients and methods: FAEE levels from 18 alcohol-dependent patients in detoxification were contrasted with those of 10 social drinkers and 10 teetotallers. FAEE in hair were determined, using headspace solid phase microextraction and gas chromatography mass spectrometry. CFAEE, as sum of the concentrations of four esters, was compared to a major FAEE, ethyl palmitate. PEth was measured in heparinized whole blood with a high pressure liquid chromatography (HPLC) method. Drinking validation criteria include self reports, phosphatidyl ethanol (PEth) in whole blood as well as the traditional markers of heavy drinking, gamma glutamyl transpeptidase (GGT), mean corpuscular volume (MCV) and carbohydrate deficient transferrin (CDT). Results: Receiver-operating characteristic (ROC) curve analysis for CFAEE, indicated a sensitivity of 100% and a specificity of 90% for a cut-off of 0.29 ng/mg. By using a cut-off of 0.4 ng/mg, CFAEE identified 94.4% correctly. CFAEE and ethyl palmitate were significantly associated (r = 0.945; P < 0.001) as were CFAEE and PEth (r = 0.527; P = 0.025). No significant correlation was found between CFAEE and total grams of ethanol consumed last month, blood-alcohol concentration at admission to the hospital, CDT, MCV, or GGT. Among the serum and blood markers, %CDT identified 47.1%, MCV 38.8% and GGT 72.2% of patients with chronic intake of higher amounts of ethanol correctly, whereas PEth achieved 100% accuracy. Conclusions: The data suggest that CFAEE is a potentially valuable marker of chronic intake of high quantities of ethanol. Furthermore, the results indicate that a reasonable and provisional FAEE cut-off to distinguish between social/moderate and heavy drinking/alcoholism in hair is 0.4 ng/mg.
- 1 January 2004
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 39 (1) , 33-38
Open AccessCONCENTRATION OF FATTY ACID ETHYL ESTERS IN HAIR OF ALCOHOLICS: COMPARISON TO OTHER BIOLOGICAL STATE MARKERS AND SELF REPORTED-ETHANOL INTAKE
Aims: In a variety of clinical and forensic situations long term use of alcohol must be monitored. In this project we explore the utility of fatty acid ethyl esters (FAEE) in this regard. Additionally, we propose a cut-off value of FAEE to distinguish teetotallers/moderate/social drinkers from alcoholics or individuals drinking at harmful levels. Patients and methods: FAEE levels from 18 alcohol-dependent patients in detoxification were contrasted with those of 10 social drinkers and 10 teetotallers. FAEE in hair were determined, using headspace solid phase microextraction and gas chromatography mass spectrometry. CFAEE, as sum of the concentrations of four esters, was compared to a major FAEE, ethyl palmitate. PEth was measured in heparinized whole blood with a high pressure liquid chromatography (HPLC) method. Drinking validation criteria include self reports, phosphatidyl ethanol (PEth) in whole blood as well as the traditional markers of heavy drinking, gamma glutamyl transpeptidase (GGT), mean corpuscular volume (MCV) and carbohydrate deficient transferrin (CDT). Results: Receiver-operating characteristic (ROC) curve analysis for CFAEE, indicated a sensitivity of 100% and a specificity of 90% for a cut-off of 0.29 ng/mg. By using a cut-off of 0.4 ng/mg, CFAEE identified 94.4% correctly. CFAEE and ethyl palmitate were significantly associated (r = 0.945; P < 0.001) as were CFAEE and PEth (r = 0.527; P = 0.025). No significant correlation was found between CFAEE and total grams of ethanol consumed last month, blood-alcohol concentration at admission to the hospital, CDT, MCV, or GGT. Among the serum and blood markers, %CDT identified 47.1%, MCV 38.8% and GGT 72.2% of patients with chronic intake of higher amounts of ethanol correctly, whereas PEth achieved 100% accuracy. Conclusions: The data suggest that CFAEE is a potentially valuable marker of chronic intake of high quantities of ethanol. Furthermore, the results indicate that a reasonable and provisional FAEE cut-off to distinguish between social/moderate and heavy drinking/alcoholism in hair is 0.4 ng/mg.
Ethyl glucuronide—the direct ethanol metabolite on the threshold from science to routine use
Aims Current biological state markers remain suboptimal with regard to sensitivity and specificity for monitoring recent alcohol consumption in various settings. Furthermore, these biomarkers can be influenced by age, gender and a variety of substances and non‐alcohol‐associated diseases and do not cover fully the time axis for alcohol intake. Ethyl glucuronide (EtG) is a non‐volatile, water‐soluble, stable, direct metabolite of ethanol that can be detected in various body fluids, tissues and hair. Shortly after the consumption even of small amounts of ethanol, EtG becomes positive. It can detect ethanol intake up to 80 hours after the complete elimination of alcohol from the body, covering a unique and important time spectrum for recent alcohol use. EtG seems to meet the need for a sensitive and specific marker to elucidate alcohol use not detected by standard testing.Design, setting, participants, methods and findings The literature was re‐viewed with a focus on possible diagnostic and therapeutic applications, currently available methods and future perspectives. To date, more than 4000 samples of body fluids, tissues and hair from approximately 1500 individuals have been assessed.Conclusions The data suggest that EtG is a useful tool in numerous settings, including alcohol and drug treatment (to detect lapse/relapse and for motivational feedback), in safety sensitive work settings where use is dangerous or in other settings where alcohol use may be risky (e.g. such as driving, work‐place, pregnancy or monitoring physicians or other professionals who are in recovery and working) or for resolving forensic questions. If the question of recent alcohol consumption has to be answered in a binary way (yes/no), such as for determining lapses, the use of EtG in urine is among the preferred tests. The use of this marker alone and complementary with other biological state markers and self‐reports is expected to lead to significant improvement in treatment outcome, therapy efficacy and cost reduction.
Ethyl glucuronide—the direct ethanol metabolite on the threshold from science to routine use
Aims Current biological state markers remain suboptimal with regard to sensitivity and specificity for monitoring recent alcohol consumption in various settings. Furthermore, these biomarkers can be influenced by age, gender and a variety of substances and non‐alcohol‐associated diseases and do not cover fully the time axis for alcohol intake. Ethyl glucuronide (EtG) is a non‐volatile, water‐soluble, stable, direct metabolite of ethanol that can be detected in various body fluids, tissues and hair. Shortly after the consumption even of small amounts of ethanol, EtG becomes positive. It can detect ethanol intake up to 80 hours after the complete elimination of alcohol from the body, covering a unique and important time spectrum for recent alcohol use. EtG seems to meet the need for a sensitive and specific marker to elucidate alcohol use not detected by standard testing.Design, setting, participants, methods and findings The literature was re‐viewed with a focus on possible diagnostic and therapeutic applications, currently available methods and future perspectives. To date, more than 4000 samples of body fluids, tissues and hair from approximately 1500 individuals have been assessed.Conclusions The data suggest that EtG is a useful tool in numerous settings, including alcohol and drug treatment (to detect lapse/relapse and for motivational feedback), in safety sensitive work settings where use is dangerous or in other settings where alcohol use may be risky (e.g. such as driving, work‐place, pregnancy or monitoring physicians or other professionals who are in recovery and working) or for resolving forensic questions. If the question of recent alcohol consumption has to be answered in a binary way (yes/no), such as for determining lapses, the use of EtG in urine is among the preferred tests. The use of this marker alone and complementary with other biological state markers and self‐reports is expected to lead to significant improvement in treatment outcome, therapy efficacy and cost reduction.